Literature DB >> 1656097

Terminal 7-methyl-guanosine cap structure on the normally uncapped 5' noncoding region of poliovirus mRNA inhibits its translation in mammalian cells.

S J Hambidge1, P Sarnow.   

Abstract

We have used an RNA transfection assay to study the translation of cellular and viral mRNAs with and without 5'-terminal m7GpppG cap structures in human tissue culture cells. HeLa cells were transfected with in vitro-transcribed hybrid RNA molecules containing the 5' noncoding regions of either luciferase or poliovirus linked to the coding region of the firefly luciferase gene. Transcripts containing a capped luciferase 5' noncoding region produced luciferase, while similar uncapped transcripts did not. In contrast, transcripts containing a capped 5' noncoding region of poliovirus accumulated 10-fold-lower levels of luciferase than similar transcripts without a terminal cap structure. Inhibition of poliovirus mRNA translation by a 5'-terminal cap structure was not observed in in vitro translation systems. This finding indicates that factors involved in cap-independent translation of poliovirus RNA are quantitatively or qualitatively different in human tissue culture cells and in in vitro translation systems. Furthermore, this study emphasizes the importance of studying translational control of mRNAs in intact cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656097      PMCID: PMC250341     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Capping of eucaryotic mRNAs.

Authors:  A J Shatkin
Journal:  Cell       Date:  1976-12       Impact factor: 41.582

2.  An RNA hairpin at the extreme 5' end of the poliovirus RNA genome modulates viral translation in human cells.

Authors:  E A Simoes; P Sarnow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Covalent linkage of a protein to a defined nucleotide sequence at the 5'-terminus of virion and replicative intermediate RNAs of poliovirus.

Authors:  J B Flanegan; R F Petterson; V Ambros; N J Hewlett; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

4.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

5.  5'-terminal structure of poliovirus polyribosomal RNA is pUp.

Authors:  M J Hewlett; J K Rose; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

6.  The 5' end of poliovirus mRNA is not capped with m7G(5')ppp(5')Np.

Authors:  A Nomoto; Y F Lee; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

7.  Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo.

Authors:  S K Jang; M V Davies; R J Kaufman; E Wimmer
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

8.  Cationic liposome-mediated RNA transfection.

Authors:  R W Malone; P L Felgner; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

9.  A protein covalently linked to poliovirus genome RNA.

Authors:  Y F Lee; A Nomoto; B M Detjen; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

10.  Efficient infection of monkey cells with DNA of simian virus 40.

Authors:  L M Sompayrac; K J Danna
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more
  12 in total

1.  Translational enhancement of the poliovirus 5' noncoding region mediated by virus-encoded polypeptide 2A.

Authors:  S J Hambidge; P Sarnow
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  Evidence for involvement of trans-acting factors in selection of the AUG start codon during eukaryotic translational initiation.

Authors:  S McBratney; P Sarnow
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

3.  General RNA binding proteins render translation cap dependent.

Authors:  Y V Svitkin; L P Ovchinnikov; G Dreyfuss; N Sonenberg
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

4.  Inhibition of translation of mRNAs containing gamma-monomethylphosphate cap structure in frog oocytes and in mammalian cells.

Authors:  Y Chen; K Perumal; R Reddy
Journal:  Gene Expr       Date:  2000

5.  Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism.

Authors:  C Wang; P Sarnow; A Siddiqui
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

Review 6.  Remarks on the mechanism of ribosome binding to eukaryotic mRNAs.

Authors:  N Sonenberg
Journal:  Gene Expr       Date:  1993

7.  Influence of Theiler's murine encephalomyelitis virus 5' untranslated region on translation and neurovirulence.

Authors:  S B Stein; L Zhang; R P Roos
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  L-Myc protein synthesis is initiated by internal ribosome entry.

Authors:  Catherine L Jopling; Keith A Spriggs; Sally A Mitchell; Mark Stoneley; Anne E Willis
Journal:  RNA       Date:  2004-02       Impact factor: 4.942

9.  Activity of the human immunodeficiency virus type 1 cell cycle-dependent internal ribosomal entry site is modulated by IRES trans-acting factors.

Authors:  Maricarmen Vallejos; Jules Deforges; Terra-Dawn M Plank; Alejandro Letelier; Pablo Ramdohr; Christopher G Abraham; Fernando Valiente-Echeverría; Jeffrey S Kieft; Bruno Sargueil; Marcelo López-Lastra
Journal:  Nucleic Acids Res       Date:  2011-04-10       Impact factor: 16.971

10.  HIV-1 transcripts use IRES-initiation under conditions where Cap-dependent translation is restricted by poliovirus 2A protease.

Authors:  Raquel Amorim; Sara Mesquita Costa; Nathalia Pereira Cavaleiro; Edson Elias da Silva; Luciana Jesus da Costa
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.